HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugstore.com

This article was originally published in The Rose Sheet

Executive Summary

Online drugstore expects to acquire 800,000-900,000 new customers in 2002, Bellevue, Wash. company reports during 1fourth quarter and year-end sales and earnings call Jan. 29. Firm notes 225,000 new customers joined the site in Q4, bringing total customer base to 2.4 mil. Net sales for fiscal 2001 reached $145.3 mil., up 32.1% from prior-year period. Fourth quarter sales were $43.5 mil., an increase of 20.2%, company says. Drugstore.com reports a loss of $282.8 mil. for the year, including a $178 mil. restructuring charge, compared to $193 mil. loss a year ago. In Q4, firm recorded loss of $182.9 mil. (including a $163 mil. charge) compared to a loss of $43.2 mil. in 2000 period. Drugstore.com expects to achieve EBITDA profitability by 2003 (2"The Rose Sheet" Jan. 14, 2002, p. 9)...

You may also be interested in...



Drugstore.com Sales Gains, Cost Reductions Expected To Yield Profit By 2003

Online retailer drugstore.com sets $305 mil.-$315 mil. revenue target for 2003 - a level more than double the firm's 2001 sales - as part of an accelerated growth initiative

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel